Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on Tuesday, plunged -0.14% from the previous trading day, before settling in for the closing price of $928.61. Within the past 52 weeks, REGN’s price has moved between $772.84 and $1211.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 19.99% over the last five years. The company achieved an average annual earnings per share of 2.10%. With a float of $106.30 million, this company’s outstanding shares have now reached $107.60 million.
The firm has a total of 13450 workers. Let’s measure their productivity. In terms of profitability, gross margin is 86.08%, operating margin of 29.18%, and the pretax margin is 34.01%.
Regeneron Pharmaceuticals, Inc. (REGN) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Regeneron Pharmaceuticals, Inc. is 3.55%, while institutional ownership is 86.64%. The most recent insider transaction that took place on Oct 01 ’24, was worth 104,878. In this transaction Director of this company sold 100 shares at a rate of $1048.78, taking the stock ownership to the 17,582 shares. Before that another transaction happened on Oct 01 ’24, when Company’s EVP Commercial sold 1,000 for $1054.06, making the entire transaction worth $1,054,060. This insider now owns 12,931 shares in total.
Regeneron Pharmaceuticals, Inc. (REGN) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 2.10% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.00% during the next five years compared to 10.31% growth over the previous five years of trading.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Trading Performance Indicators
Regeneron Pharmaceuticals, Inc. (REGN) is currently performing well based on its current performance indicators. A quick ratio of 4.62 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.58. Likewise, its price to free cash flow for the trailing twelve months is 30.71.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 37.76, a number that is poised to hit 11.69 in the next quarter and is forecasted to reach 47.26 in one year’s time.
Technical Analysis of Regeneron Pharmaceuticals, Inc. (REGN)
Analysing the last 5-days average volume posted by the [Regeneron Pharmaceuticals, Inc., REGN], we can find that recorded value of 0.64 million was better than the volume posted last year of 0.51 million. As of the previous 9 days, the stock’s Stochastic %D was 10.16%. Additionally, its Average True Range was 22.03.
During the past 100 days, Regeneron Pharmaceuticals, Inc.’s (REGN) raw stochastic average was set at 2.71%, which indicates a significant decrease from 7.54% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 15.30% in the past 14 days, which was lower than the 21.26% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1,077.93, while its 200-day Moving Average is $1,014.26. Now, the first resistance to watch is $931.89. This is followed by the second major resistance level at $936.45. The third major resistance level sits at $940.52. If the price goes on to break the first support level at $923.26, it is likely to go to the next support level at $919.19. Now, if the price goes above the second support level, the third support stands at $914.63.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Key Stats
Market capitalization of the company is 102.21 billion based on 110,235K outstanding shares. Right now, sales total 13,117 M and income totals 3,954 M. The company made 3,547 M in profit during its latest quarter, and 1,432 M in sales during its previous quarter.
